Get the Stockscreener App
3.0699
2.14%
-0.0672
After Hours:
2.70
-0.3699
-12.05%
Dermata Therapeutics Inc stock is traded at $3.0699, with a volume of 41,472.
It is down -2.14% in the last 24 hours and down -27.08% over the past month.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
See More
Previous Close:
$3.1371
Open:
$3.0694
24h Volume:
41,472
Relative Volume:
0.33
Market Cap:
$2.09M
Revenue:
-
Net Income/Loss:
$-11.27M
P/E Ratio:
-0.1434
EPS:
-21.4132
Net Cash Flow:
$-9.40M
1W Performance:
+0.98%
1M Performance:
-27.08%
6M Performance:
-60.59%
1Y Performance:
-74.18%
1-Day Range:
$2.95
$3.09
1-Week Range:
$2.90
$3.32
52-Week Range:
$2.90
$23.70
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
3.0699 | 2.14M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
Can Dermata Therapeutics Inc. stock sustain market leadershipJuly 2025 Setups & High Yield Equity Trading Tips - newser.com
Has Dermata Therapeutics Inc. formed a bullish divergence2025 Institutional Moves & Free Weekly Chart Analysis and Trade Guides - newser.com
Order flow analysis tools used on Dermata Therapeutics Inc.Portfolio Performance Report & Stock Market Timing Techniques - newser.com
Can Dermata Therapeutics Inc. Equity Warrant stock resist market sell offsJuly 2025 PreEarnings & Intraday High Probability Alerts - newser.com
Institutional scanner results for Dermata Therapeutics Inc. Equity WarrantJuly 2025 Catalysts & Daily Risk Controlled Trade Plans - newser.com
Visualizing Dermata Therapeutics Inc. stock with heatmaps2025 Key Lessons & Step-by-Step Trade Execution Guides - newser.com
What data driven models say about Dermata Therapeutics Inc.’s futureWeekly Investment Summary & AI Powered Trade Plan Recommendations - newser.com
Dermata Switches Gears From Prescriptions To OTC Skincare - Finimize
How to manage a losing position in Dermata Therapeutics Inc.Portfolio Update Summary & Advanced Swing Trade Entry Plans - newser.com
Heatmap analysis for Dermata Therapeutics Inc. and competitorsWeekly Gains Summary & Technical Entry and Exit Tips - newser.com
Tools to monitor Dermata Therapeutics Inc. recovery probability2025 Year in Review & Free High Accuracy Swing Entry Alerts - newser.com
Intraday pattern recognizer results for Dermata Therapeutics Inc. Equity Warrant2025 Market Outlook & Fast Momentum Stock Entry Tips - newser.com
Dermata Therapeutics announces strategic pivot to OTC skin careSEC filing - MarketScreener
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results - ACCESS Newswire
Dermata (NASDAQ: DRMA) pivots to OTC skincare, plans once-weekly acne kit launch mid-2026 - Stock Titan
How to use Fibonacci retracement on Dermata Therapeutics Inc.2025 Technical Overview & Reliable Volume Spike Alerts - newser.com
What analysts say about Dermata Therapeutics Inc stockSupport Level Holds & Turn Bull Runs into Life-Changing Wealth - earlytimes.in
Why Dermata Therapeutics Inc. stock is trending among retail tradersMarket Sentiment Summary & Breakout Confirmation Trade Signals - newser.com
Analyzing drawdowns of Dermata Therapeutics Inc. with statistical toolsEarnings Risk Summary & Community Verified Watchlist Alerts - newser.com
Is Dermata Therapeutics Inc. stock a buy on dipsJobs Report & High Win Rate Trade Alerts - newser.com
What analysts say about Dermata Therapeutics Inc Equity Warrant stockStock Split Announcements & Rapid Portfolio Growth - earlytimes.in
Trend analysis for Dermata Therapeutics Inc. Equity Warrant this week2025 Support & Resistance & Daily Oversold Bounce Ideas - newser.com
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):